Oncology & Hematology Coding Alert

Xofigo is radium Ra 223 dichloride that is available as an injection. Your physician will use Xofigo to treat metastatic castration-resistant prostate cancer (mCRPC), i.e. prostate cancer that is resistant to medical or surgical treatments that lower testosterone. “In patients considered eligible to receive Xofigo, the patient would be symptomatic bone metastases and have no known visceral metastatic disease,” says Kelly C. Loya, CPC-I, CHC, CPhT, CRMA, Director of Reimbursement and Advisory Services, Altegra Health, Inc. Therefore, look for documentation supporting the patient’s symptoms of bone involvement. Xofigo is distributed to the bones with the majority of the remainder being excreted into the intestine.  The medication helps kill the cancer cells with limited damage to the nearby healthy cells. 

Dosing: Your physician will prescribe a dose regimen of Xofigo for 50 kBq (1.35 microcurie) per kg body weight. The patient will receive total of 6 injections at intervals of 4 weeks. 

Formulation: Xofigo is available as a single-use vial at a concentration of 1,000 kBq/mL (27 microcurie/mL) with a total radioactivity of 6,000 kBq/vial (162 microcurie/vial) at the reference date.